A follow-up study of the prevalence of valvular heart abnormalities in hyperprolactinemic patients treated with cabergoline.
Authors
Drake, WStiles, C
Bevan, J
Karavitaki, N
Trainer, Peter J
Rees, D
Richardson, T
Baldeweg, S
Stojanovic, N
Murray, R
Toogood, A
Martin, N
Vaidya, B
Han, T
Steeds, R
Baldeweg, F
Sheikh, U
Kyriakakis, N
Parasuraman, S
Taylor, L
Butt, N
Anyiam, S
Affiliation
Dept Endocrinology, St Bartholomew's Hospital, London EC1A 7BEIssue Date
2016-08-29
Metadata
Show full item recordAbstract
CONTEXT Uncertainty exists whether the long-term use of ergot-derived dopamine agonist (DA) drugs for the treatment of hyperprolactinemia may be associated with clinically significant valvular heart disease; and whether current regulatory authority guidelines for echocardiographic screening are clinically appropriate.Citation
A follow-up study of the prevalence of valvular heart abnormalities in hyperprolactinemic patients treated with cabergoline. 2016, jc20162224 J Clin Endocrinol MetabJournal
The Journal of Clinical Endocrinology and MetabolismDOI
10.1210/jc.2016-2224PubMed ID
27571182Type
ArticleLanguage
enISSN
1945-7197ae974a485f413a2113503eed53cd6c53
10.1210/jc.2016-2224
Scopus Count
Collections
Related articles
- A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists.
- Authors: Drake WM, Stiles CE, Howlett TA, Toogood AA, Bevan JS, Steeds RP, UK Dopamine Agonist Valvulopathy Group
- Issue date: 2014 Jan
- Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.
- Authors: Vroonen L, Lancellotti P, Garcia MT, Dulgheru R, Rubio-Almanza M, Maiga I, Magne J, Petrossians P, Auriemma R, Daly AF, Beckers A
- Issue date: 2017 Jan
- Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas.
- Authors: Auriemma RS, Pivonello R, Perone Y, Grasso LF, Ferreri L, Simeoli C, Iacuaniello D, Gasperi M, Colao A
- Issue date: 2013 Sep
- Cardiac valvular abnormalities associated with use and cumulative exposure of cabergoline for hyperprolactinemia: the CATCH study.
- Authors: Budayr A, Tan TC, Lo JC, Zaroff JG, Tabada GH, Yang J, Go AS
- Issue date: 2020 Feb 19
- Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline.
- Authors: Lafeber M, Stades AM, Valk GD, Cramer MJ, Teding van Berkhout F, Zelissen PM
- Issue date: 2010 Apr